Hypertension, Ischemic Stroke, Transient Ischemic Attack
Conditions
Brief summary
This study evaluates the effectiveness of fimasartan-based antihypertensive treatment and prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients. All participants will receive fimasartan, and the investigators will follow them up for 6 months.
Interventions
None listed
Sponsors
Boryung Pharmaceutical Co., Ltd
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ischemic stroke or transient ischemic attack occurs after 7 days to 3 months. * Mean blood pressure measured 3 times at the first visit (Visit 1) should be over 140 mmHg for systolic blood pressure or 90 mmHg for diastolic blood pressure * Suitable for administration of fimasartan * The life expectancy should be over 6 months.
Exclusion criteria
* Patients already treated with antihypertensive medications * Hemorrhagic stroke patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BP | 24 weeks | Blood pressure control rate(\<140/90 mmHg) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| mRS | 4, 12, 24 weeks | mRS changes |
| Fimasartan-based treatment | 24 weeks | Fimasartan-based treatment modalities |
| Fimasartan starting point | 24 weeks | Fimasartan starting point after stroke |
| Stroke recurrence | 24 weeks | Rate of stroke recurrence |
| BP | 4, 12 weeks | Blood pressure control rate(\<140/90 mmHg) |
| Mortality rates from cardiovascular disease | 24 weeks | Mortality rates from cardiovascular disease |
| Mortality rates of any cause | 24 weeks | Mortality rates of any cause |
| Adverse events | 24 weeks | Adverse events related to antihypertensive treatments |
| Cardiovascular events | 24 weeks | Incidence of cardiovascular events |
Countries
South Korea
Outcome results
None listed